Compare REZI & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REZI | IMVT |
|---|---|---|
| Founded | 2018 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Wholesale Distributors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 5.8B |
| IPO Year | 2018 | 2019 |
| Metric | REZI | IMVT |
|---|---|---|
| Price | $40.15 | $27.08 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $39.67 | $33.00 |
| AVG Volume (30 Days) | 1.1M | ★ 1.5M |
| Earning Date | 05-12-2026 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,472,000,000.00 | N/A |
| Revenue This Year | $6.81 | N/A |
| Revenue Next Year | $3.62 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 10.52 | N/A |
| 52 Week Low | $17.22 | $13.36 |
| 52 Week High | $45.29 | $30.09 |
| Indicator | REZI | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 59.99 | 51.37 |
| Support Level | $39.36 | $24.63 |
| Resistance Level | $43.30 | $27.71 |
| Average True Range (ATR) | 1.17 | 1.35 |
| MACD | 0.01 | -0.13 |
| Stochastic Oscillator | 63.54 | 40.67 |
Resideo Technologies Inc is a manufacturer and developer of technology-driven products and components that provide critical comfort, energy management, and safety and security solutions. The company has two reportable segments; Products and Solutions segment offers temperature and humidity control, energy products and solutions, water and air solutions, smoke and carbon monoxide detection home safety products, security panels, sensors, peripherals, wire and cable, communications devices, video cameras, other home-related lifestyle convenience solutions; and ADI Global Distribution segment includes wholesale distributor of low-voltage security products including access control, fire detection, security, and video products. It derives majority of its revenue from the United States.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.